Barclays
PHAT icon

Barclays’s Phathom Pharmaceuticals PHAT Stock Holding History

Barclays’s Portfolio PHAT Stock Details PHAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$453K Buy
41,777
+16,420
+65% +$187K ﹤0.01% 3284
2026
Q1 		$282K Sell
25,357
-59,502
-70% -$752K ﹤0.01% 3506
2025
Q4 		$1.41M Sell
84,859
-43,497
-34% -$621K ﹤0.01% 3191
2025
Q3 		$1.51M Buy
128,356
+46,186
+56% +$477K ﹤0.01% 3094
2025
Q2 		$788K Buy
82,170
+27,268
+50% +$151K ﹤0.01% 3495
2025
Q1 		$344K Sell
54,902
-21,561
-28% -$131K ﹤0.01% 3746
2024
Q4 		$621K Buy
76,463
+18,656
+32% +$231K ﹤0.01% 3691
2024
Q3 		$1.05M Buy
57,807
+45,402
+366% +$635K ﹤0.01% 3326
2024
Q2 		$128K Sell
12,405
-15,794
-56% -$163K ﹤0.01% 3791
2024
Q1 		$299K Sell
28,199
-21,473
-43% -$182K ﹤0.01% 3900
2023
Q4 		$454K Buy
49,672
+36,437
+275% +$314K ﹤0.01% 3941
2023
Q3 		$137K Buy
13,235
+2,422
+22% +$33.2K ﹤0.01% 3467
2023
Q2 		$155K Sell
10,813
-1,713
-14% -$19.8K ﹤0.01% 3371
2023
Q1 		$89.4K Buy
12,526
+3,647
+41% +$32K ﹤0.01% 4239
2022
Q4 		$99.6K Buy
8,879
+7,903
+810% +$81.5K ﹤0.01% 4224
2022
Q3 		$11K Sell
976
-3,791
-80% -$36.1K ﹤0.01% 4268
2022
Q2 		$40K Sell
4,767
-2,200
-32% -$22.6K ﹤0.01% 4126
2022
Q1 		$94K Buy
+6,967
New +$113K ﹤0.01% 3813

Other funds holding PHAT

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10B AUM 10.61% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
GKIM
GW&K Investment Management Boston, Massachusetts $12.8B AUM 48.82% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Barclays's PHAT Position: Q2 2026 in Review

Barclays increased its Phathom Pharmaceuticals (PHAT) stake by 65% in Q2 2026, buying an estimated $187K and bringing the position to 41,777 shares worth $453K. The position accounts for ﹤0.01% of the portfolio, ranked #3284.

Barclays first reported a position in PHAT in Q1 2022 and has held it in 18 quarters since. The position peaked at $1.51M in Q3 2025. 162 funds tracked by Wall St. Rank hold PHAT as of Q2 2026.

  • Barclays held 41,777 shares of Phathom Pharmaceuticals worth $453K as of Q2 2026.
  • Barclays bought 16,420 Phathom Pharmaceuticals shares in Q2 2026, an estimated $187K.
  • Phathom Pharmaceuticals made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #3284 holding.
  • Barclays first reported a position in Phathom Pharmaceuticals in Q1 2022 and has held it in 18 quarters since.
  • Barclays's Phathom Pharmaceuticals position peaked at $1.51M in Q3 2025.
  • 162 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.